Valens Signs Multi-year Cannabis Extraction & Product R&D Agreement with Harvest One
Kelowna, B.C., November 14th, 2018 – Valens GroWorks Corp. (CSE: VGW) (OTC: MYMSF) (the “Company” or “Valens”), a licensed, vertically integrated provider of cannabis products and services focused on various proprietary extraction methodologies, distillation, cannabinoid isolation and purification, as well as associated quality testing is pleased to announce that it has entered into a multi-year Extraction Services Agreement (the “Agreement”) with Harvest One (TSXV:HVT) for cannabis extraction and value-added services. Under the terms of the Agreement, Harvest One’s subsidiary, United Greeneries, will ship bulk quantities of dried cannabis to Valens over an initial three-year term. The Company will receive and process the cannabis on a fee for service basis into bulk resin or other cannabis oil derivative products.
The Company will also conduct R&D services for Harvest One to support their product line development including health and wellness products, beverages, vape pens, and nutraceuticals using cannabis oil derivative products. The significance of these products is reflected in the more developed markets in the United States where raw flower makes up less than half of the products sold.
“We are excited for the opportunity to utilize our extraction services and R&D technology platform to support Harvest One in delivering innovative, high quality consumer packaged goods to the market,” said Tyler Robson, CEO of Valens. “Valens’ expertise in both cannabis extraction and cannabis derivatives offers Harvest One a competitive advantage in the marketplace, especially considering the proven consumer uptake and shelf life stability benefits we are able to make available through the use of SōRSE™ technology. The team at Valens intends to work closely with Harvest One to put the best possible products on the shelves for Canadian consumers.”
“Harvest One’s agreement with Valens represents a valuable opportunity to accelerate our product development strategy,” said Grant Froese, CEO of Harvest One. “We are excited to leverage Valens’ industry leading expertise to further expand our recreational, and health and wellness products, under United Greeneries, Satipharm and Dream Water. Furthermore, this partnership gives Harvest One the ability to diversify our medical product offerings to better serve our patients.”
About Harvest One
Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world. The Company’s range of lifestyle solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through three wholly-owned subsidiaries: United Greeneries, a Licensed Producer; Satipharm (medical and nutraceutical); and Dream Water (consumer).
About Valens GroWorks
The Company’s investor deck can be found here.
For further information, please contact:
Notice regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.